Sanofi (SNY): Today's Featured Drugs Winner
(
) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.4%. By the end of trading, Sanofi rose 27 cents (0.8%) to $34.03 on light volume. Throughout the day, 2.2 million shares of Sanofi exchanged hands as compared to its average daily volume of 3.7 million shares. The stock ranged in a price between $33.68-$34.23 after having opened the day at $34.05 as compared to the previous trading day's close of $33.76. Other companies within the Drugs industry that increased today were:
(
), up 23.5%,
(
), up 15.6%,
(
), up 14.9%, and
TheStreet Recommends
(
), up 13.3%.
Sanofi, together with its subsidiaries, researches, develops, manufactures, and markets healthcare products worldwide. Sanofi has a market cap of $92.55 billion and is part of the
sector. The company has a P/E ratio of 18.6, above the average drugs industry P/E ratio of 12.4 and above the S&P 500 P/E ratio of 17.7. Shares are down 5.6% year to date as of the close of trading on Wednesday. Currently there are four analysts that rate Sanofi a buy, no analysts rate it a sell, and three rate it a hold.
TheStreet Ratings rates Sanofi as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.
- You can view the full Sanofi Ratings Report.
On the negative front,
Chelsea Therapeutics International
(
), down 31.3%,
(
), down 21.7%,
(
), down 17.4%, and
(
), down 12.8%, were all losers within the drugs industry with
(
) being today's drugs industry loser.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
- Find other investment ideas from our top rated ETFs lists.
null
